Literature DB >> 16781260

Treatment of pain during medical abortion.

Gillian Penney1.   

Abstract

A structured literature review was undertaken to determine, in the context of early medical abortion, the proportion of women who require analgesia, the predictors of analgesia requirement and the most appropriate analgesia regimen. Studies from different centers show wide variations in analgesia use, but, overall, around 75% of women use narcotic analgesics on the day of prostaglandin administration. Differences are likely to be due to differences in policies for offering analgesia rather than differences in patient characteristics. The following characteristics are consistently associated with increased requirement for analgesia: increasing gestation, younger patient age, nulliparity and White race. A regimen comprising 325-500 mg of paracetamol (acetaminophen) with 10 mg of dihydrocodeine or 30 mg of codeine has been used by thousands of women without apparent problems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781260     DOI: 10.1016/j.contraception.2006.03.002

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

1.  Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial.

Authors:  EmmaKate B Friedlander; Reni Soon; Jennifer Salcedo; James Davis; Mary Tschann; Bliss Kaneshiro
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

Review 2.  Pain management for medical abortion before 14 weeks' gestation.

Authors:  John J Reynolds-Wright; Mulat A Woldetsadik; Chelsea Morroni; Sharon Cameron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-13

3.  Intravenous paracetamol versus intramuscular pethidine in relief of labour pain in primigravid women.

Authors:  Mohammad-Hasan Abdollahi; Mahdiye Mojibian; Alireza Pishgahi; Fatemeh Mallah; Shahla Dareshiri; Sahar Mohammadi; Mohammad Naghavi-Behzad
Journal:  Niger Med J       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.